Abstract:Abstract Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for various types of cancers. Nevertheless, the low response rate of α-PD-1/PD-L1 therapy remains to be resolved. For most cancer patients, PD-1/PD-L1 pathway is not the sole speed-limiting factor of antitumor immunity, and it is insufficient to motivate effective antitumor immune response by blocking PD-1/PD-L1 axis. It has been validated that some combination therapies, including α-PD-1/PD-L1 plus chemotherapy, radiotherapy, angiogenesis inhibitors, targeted therapy, other immune checkpoint inhibitors, agonists of the co-stimulatory molecule, stimulator of interferon genes agonists, fecal microbiota transplantation, epigenetic modulators, or metabolic modulators, have superior antitumor efficacies and higher response rates. Moreover, bifunctional or bispecific antibodies containing α-PD-1/PD-L1 moiety also elicited more potent antitumor activity. These combination strategies simultaneously boost multiple processes in cancer-immunity cycle, remove immunosuppressive brakes, and orchestrate an immunosupportive tumor microenvironment. In this review, we summarized the synergistic antitumor efficacies and mechanisms of α-PD-1/PD-L1 in combination with other therapies. Moreover, we focused on the advances of α-PD-1/PD-L1-based immunomodulatory strategies in clinical studies. Given the heterogeneity across patients and cancer types, individualized combination selection could improve the effects of α-PD-1/PD-L1-based immunomodulatory strategies and relieve treatment resistance.

The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy

Progress in PD-1/PD-L1 inhibitors combined with other approaches in the treatment of non-small cell lung cancer

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1

Advances of PD-1/PD-L1 inhibitors in tumor immunotherapy

Application of PD-1 Blockade in Cancer Immunotherapy

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Combining PD-1/PD-L1 inhibitor and PARP inhibitor: a new perspective on the treatment of triple negative breast cancer

Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients

Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy

PD-1/PD-L1 Counterattack Alliance: Multiple Strategies for Treating Triple-Negative Breast Cancer

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis

Research Progress in PD-1/PD-L1 antibodies treating human cancers

Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer